PELARGONIUM SIDOIDES RESEARCH LITERATURE

PRODUCT MONOGRAPH

Acute respiratory tract infections are the most common diseases treated in general and paediatric practices and affect all age groups, particularly during the winter months. During an epidemic they can account for up to 50% of all medical consultations [Marre et al. 2006]. Medical consultations for colds and influenza alone cost between 650 and 850 million euros a year in Germany [Fintelmann 2005]. The fact that 90 to 95% of cases are virus-mediated makes this an even greater therapeutic challenge [DGPI Handbuch 2003].

EPS 7630 EXTRACT

Acute respiratory tract infections (RTIs) are common and can affect all age groups, particularly during the winter months. Most RTIs – between 90 - 95% – such as the common cold, acute sinusitis and bronchitis are caused by viruses. As antibiotics fight bacterial infections, not viruses, they are entirely ineffective in treating viral-induced respiratory tract infections. Inappropriate antibiotic use is the main cause for the globally increasing antibiotic resistance. It is, therefore, becoming increasingly important to find effective alternatives.

P.SIDOIDES - A SUMMARY

Pelargonium sidoides, commonly known as African geranium, is a medicinal herb. It is also sold under the brand names Kaloba and Umckaloabo as a plant-derived pharmaceutical. Pelargonium sidoides is very effective for treating acute bronchitis. It increases the body’s natural healing rate. Studies have found that 40-60% of patients suffering from acute bronchitis fully resolve their symptoms within a week of Pelargonium sidoides supplementation. Some people reported experiencing benefits after just two to three days. People that are not cured after a week still experience benefits from Pelargonium sidoides supplementation, since it can treat the symptoms associated with bronchitis, including headache, fever, fatigue, cough, chest pain while coughing, sputum in the lungs, bronchi, and nasal dripping.

JOURNAL OF ETHNOPHARMACOLOGY:

A historical, scientific and commercial perspective on the medicinal use of Pelargonium sidoides.

UNIVERSITY HOSPITAL PAEDIATRICS, MAINZ, GERMANY:

Efficacy and tolerability of EPs 7630 (P. sidoides) in patients (aged 6–18 years old) with acute bronchitis - a randomized, double-blind, placebo-controlled clinical dose-finding study.

INSTITUTE OF PHARMACY, PHARMACEUTICAL BIOLOGY, FREIE UNIVERSITÄT BERLIN:

Antimicrobial, antiviral and immunomodulatory activity studies of Pelargonium sidoides (EPs® 7630) in the context of health promotion.

UNIVERSITATSKLINIKUM FREIBURG, GERMANY:  

The Pelargonium  sidoides extract  EPs 7630 drives the innate immune defense.

ADVANCES IN PHARMACOEPIDEMIOLOGY & DRUG SAFETY:

Safety and tolerability of EPs 7630 (P. sidoides) in clinical trials.

JOURNAL OF APPLIED MICROBIOLOGY:

Components derived from Pelargonium sidoides stimulate macrophage killing of Mycobacterium species.

PHYTOMEDICINE:

Efficacy and safety of an extract of Pelargonium sidoides (EPs 7630) in adults with acute bronchitis - a randomised, double-blind, placebo-controlled trial.

PHYTOMEDICINE:

Pelargonium sidoides for acute bronchitis - A systematic review and meta-analysis.